3-Heptanone as a potential new marker for valproic acid therapy

Journal of Breath Research

Volumn 3, Issue 1, 2009, Pages

  Erhart, S ^a   Amann, A ^b   Haberlandt, E ^a   Edlinger, G ^a   Schmid, A ^a,b   Filipiak, W ^a,b   Schwarz, K ^a,b   Mochalski, P ^a,b,c   Rostasy, K ^a   Karall, D ^a   Scholl Burgi S ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c INSTITUTE OF NUCLEAR PHYSICS   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

3 HEPTANONE; HEPTANE DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; BREATH ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; HEALTH SURVEY; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 68149131136     PISSN: 17527155     EISSN: 17527163     Source Type: Journal    
DOI: 10.1088/1752-7155/3/1/016004     Document Type: Article

References (17)

1. Amann A et al 2004 Applications of breath gas analysis in medicine Int. J. Mass. Spectrom. Ion. Process. 239 227-33
2. Amann A and Smith D (ed) 2005 Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring (Singapore: World Scientific Publishing)
3. Janovsky U et al 2005 Breath gas analysis for pediatric patients with propionic acidaemia Breath Analysis for Clinical Diagnosis an Therapeutic Monitoring ed A Amann and D Smith (Singapore: World Scientific Publishing) p 401
4. Kostrouchov M, Kostrouch Z and Kostrouchov M 2007 Valproic acid, a molecular lead to multiple regulatory pathways Folia. Biol. 53 37-49
5. Lheureux P E R et al 2005 Science review: carnitine in the treatment of valproic acid-induced toxicity-what is the evidence? Crit. Care. 9 431-40
6. Perucca E 2002 Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience CNS Drugs. 16 695-714
7. Krämer G and Walden J 2002 Valproinsäure 2nd edn (Berlin: Springer)
8. Löscher W 1999 Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action Prog. Neurobiol. 58 31-59
9. Dickinson R G et al 1989 Urinary excretion of valproate and some metabolites in chronically treated patients Ther. Drug. Monit. 11 127-33
10. Matsumoto I, Kuhara T and Yoshino M 1976 Metabolism of branched medium chain length fatty acid. II-beta-oxidation of sodium dipropylacetate in rats Biomed. Mass. Spectrom 3 235-40
11. Ito M et al 1990 The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl CoA dehydrogenase Biochim. Biophys. Acta. 1034 213-8
12. Li J et al 1991 Mitochondrial metabolism of valproic acid Biochemistry 30 388-94
13. Walker V and Mills G A 2001 Urine 4-heptanone: a β-oxidation product of 2-ethylhexanoic acid from plasticizers Clin. Chim. Acta. 306 51-61
14. Amann A et al 2005 Exhaled breath gas as a biochemical probe during sleep Breath Analysis for Clinical Diagnosis an Therapeutic Monitoring ed A Amann and D Smith (Singapore: World Scientific Publishing) p 305
15. Wehinger A et al 2007 Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas Int. J. Mass. Spectrom. 265 49-59
16. Su T and Chesnavich W J 1982 Parametrization of the ion-polar molecule collision rate-constant by trajectory calculations J. Chem. Phys. 76 5183-5
17. Eyer F et al 2005 Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy J. Clin. Psychopharmacol. 25 376-80